Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

View:
Post by ENEMENEMYNEMO on Mar 03, 2024 10:33am

GCAR

Do we know if ONC is pursuing collaboration with GCAR?
Comment by Azzak34 on Mar 03, 2024 11:24am
Not sure. After Pancan they seemed to infer they would now undertake the Pancreatic trials in house but anything is certainly possible. 
Comment by Noteable on Mar 03, 2024 11:47am
January 10, 2024 - Open letter from PanCAN President & CEO Julie Fleshman on the closure of Precision Promise platform and the strategic alliance with GCAR. "After four years of operation and key learnings, we recently made the decision to re-evaluate the study to determine if there were opportunities to innovate and scale the study as well as create more operational efficiencies.   ...more  
Comment by Noteable on Mar 03, 2024 11:56am
January 09, 2024 - Open letter from GCAR’s CEO, Dr. Meredith Buxton " The relationship between PanCAN and GCAR spans many years, as GCAR’s CEO, Dr. Meredith Buxton, played a key role in crafting the original Precision Promise protocol. The alliance between PanCAN and GCAR represents a dynamic synergy, harnessing the strengths of both organizations to accelerate pancreatic cancer ...more  
Comment by Noteable on Mar 07, 2024 4:42pm
March 07, 2024 - Matt Coffey confirms ONCY partnership with GCAR during today's Full Year 2023 Financial conference call.
Comment by canadafan on Mar 07, 2024 5:29pm
What is GCAR?  
Comment by Azzak34 on Mar 07, 2024 5:33pm
Give it a Goog Cfan, it's good news. Very good news! 
Comment by Noteable on Mar 07, 2024 5:40pm
Learn to click on the subject message trail to find the answer to your question .... but it's all good as Azzak pointed out.
Comment by Noteable on Mar 07, 2024 5:43pm
Here's the thread:  https://stockhouse.com/companies/bullboard/t.onc/oncolytics-biotech-ord-shs?threadid=35911938
Comment by Noteable on Mar 07, 2024 5:56pm
And canadafan, I suggest that you listen to the conference call once again ... because ONCY is a LATE STAGE Biotech company that has addressed manufacturing over the course of 2023 and is now going into registration studies and regulatory approval.  While early-stage biotechs focus on developing and testing their products, late-stage biotechs shift their focus to manufacturing ...more  
Comment by Azzak34 on Mar 07, 2024 5:45pm
GCAR must be the CRO mentioned yesterday. Taking the place of Pancan, I imagine at their suggestion. Great sign!!! 
Comment by JohnnyYeg on Mar 07, 2024 8:29pm
Chew on this... with a nice full bodied Shiraz!! https://pancan.org/news/pancan-announces-a-strategic-alliance-with-gcar-for-precision-promise/
Comment by askretka on Mar 10, 2024 2:31pm
RE: GCAR   From 07 March Transcript.  "We continue to develop a study protocol that utilizes an adaptive design, building on the positive results from the GOBLET study. The registrational strategy for PDAC will incorporate learnings from our previous interactions with the Pancreatic Cancer Action Network also known as PanCAN, and ongoing conversations with their newly ...more  
Comment by canadafan on Mar 10, 2024 3:28pm
This information looks terrific. The larger pharm general market is looking to expand via acquisitions. Onc has teamed up with GCAR, which is affwith previous PanCan. so, both on a micro & macro level the outside looking in, is favourable for ONC. All said, there needs to be & is expected to be a partnership this year. A complete buy- out. Which IMHO, most would prefer, could happen ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities